1-2 of 2
Thomas J. Rutherford
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR05: An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab

Free
Wei Wei, Mark F. Brady, Tsun-Yee Tsang, Vinod Vathipadiekal, Robert A. Burger, Robert S. Mannel, Parviz Hanjani, Warner K. Huh, Elizabeth M. Swisher, Thomas J. Rutherford, Janos L. Tanyi, Julian C. Schink, Shashikant B. Lele, Paul A. DiSilvestro, Michael J. Birrer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_1): PR05.
https://doi.org/10.1158/1538-8514.TUMANG15-PR05
Published: 01 December 2015
View articletitled, Abstract PR05: An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab
Journal Articles

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)

Free
Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, Francesca Casagrande, Marta Bellone, Maysa Abu-Khalaf, Natalia Buza, Fattaneh A. Tavassoli, Pei Hui, Dominik Rüttinger, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli, Alessandro D. Santin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 57–66.
https://doi.org/10.1158/1535-7163.MCT-09-0675
Published: 12 January 2010
View articletitled, Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)
Open the PDF for Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201) in another window